Zydus’ generic of hormone therapy patch gets U.S. FDA nod

The product is eligible for the 180-day exclusivity period available to certain first approved applicants under the CGT pathway, subject to the provisions of the U.S. Federal Food, Drug, and Cosmetic Act.